阿聯酋航空推新冠疫苗接種計劃
阿聯酋航空公布,集團與杜拜衛生局及衛生與預防部合作,由星期一開始,為駐守阿聯酋總部的員工推出新型冠狀病毒疫苗接種計劃。計劃已於1月18日早上展開,為前線工作人員接種疫苗,包括機艙服務員、於飛行甲板上工作的地勤人員及其他以營運工作為主的員工。
阿聯酋航空集團已獲阿聯酋衛生當局批准,為身處阿聯酋各個公司地點的員工接種美國輝瑞(Pfizer)(PFE.US)藥廠和德國醫藥公司BioNTech(BNTX.US)共同研發的疫苗,或國藥研發的疫苗。疫苗接種計劃以每天12小時的運作模式持續進行,以確保最多的前線員工可以完成接種。身處阿聯酋的阿聯酋航空集團員工亦可選擇於政府指定的醫療中心及診所接種疫苗。(el/k) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.